A double-blind placebo-controlled dose-response trial clear inferiority of efficacy in black patients. A single of nebivolol, a cardioselective beta-blocking drug which daily dose of 5 mg was appropriate, with no evident also induces endothelium-dependent dilatation via nitric advantage at 10 mg. The drug was well tolerated, even oxide, has been performed. Nebivolol reduced blood at 10 mg daily. BP control was achieved largely in the pressure (BP) in a dose dependent way, and was shown absence of typical side effects of beta-blockade. The to be effective given once daily, without appreciable difcombination of properties of nebivolol renders it an ferences between peak and trough drug levels. There attractive addition to the antihypertensive repertoire. was no postural component to the BP fall. There was no
Introduction
pressure of at least 95 mm Hg at the end of a 1 month Nebivolol is a highly cardioselective beta-adrenergic placebo 'run-in' period. Patients previously either blocking agent, devoid of intrinsic sympathomitreated or untreated could be recruited. Exclusion metic activity. 1, 2 It has been shown to control blood criteria are listed in Table 1 . pressure (BP) over 24 h with dosage once daily. [3] [4] [5] [6] [7] The protocol of the trial is summarized in Table  Nebivolol induces endothelium-dependent 2. After initial assessment, qualifying patients were arterial and venous dilatation via the l-argininenitric oxide pathway. [8] [9] [10] At similar antihyperten- instructed to stop any antihypertensive medication Thus from randomization to the end of doubleduring the next 2 weeks. They were then given sinblind treatment, assessments were made at trough gle-blind once-daily placebo for 4 weeks. Those drug level, 23-25 h from dosing, and also at peak qualifying were then, by a computer-generated randrug level 2 h from dosing. All BP measurements on domization procedure constructed in blocks of six, each patient were made by the same investigator, in assigned double-blind to placebo, or to nebivolol the same room, at the same time of day, using a stan-0.5, 1.0, 2.5, 5 or 10 mg once daily, to be continued dard mercury sphygmomanometer. The cuff bladder for 1 month. All tablets were identical in appearance was required to be at least 30 cm long and 13 cm and taste, and were to be taken each morning at wide; an appropriately large cuff was used if the arm breakfast, except on the occasion of clinic visits (see circumference was more than 34 cm. At the first below). Drugs which could affect the antihypertenvisit, BP was assessed in both arms; if a difference sive action of nebivolol (eg, tricyclic antidepressof more than 5 mm Hg was found, the arm with the ants, monoamine oxidase inhibitors or corticohigher value was taken, otherwise the right arm was steroids) were not allowed.
used. The same arm was subsequently employed for Other medications needed for the treatment of BP measurement in each patient throughout the concurrent disease were permitted provided they trial. remained unchanged throughout the trial. Major
At each visit heart rate was counted supine and dietary modifications, as for weight reduction or salt standing, and body weight was measured. Twelverestriction, were not allowed. During double-blind lead electrocardiography (ECG) was recorded at the therapy, visits were scheduled at 2 and 4 weeks.
end of the placebo run-in period and at the end of Patients were permitted to withdraw voluntarily double-blind therapy. at any time for any reason; they were also withBlood samples for routine haematology and biodrawn if a serious adverse event occurred, if the chemistry, and urine samples for routine testing double-blind code was broken prematurely, if the were obtained at the end of the placebo run-in and supine diastolic pressure was 120 mm Hg or more, double-blind treatment periods. or for any other relevant reason at the discretion of At each visit subjects were asked the questions: the investigator. If the supine diastolic pressure was 'Did you experience any benefit from treatment?'; at least 115 mm Hg and at most 119 mm Hg, the and 'Has treatment upset you in any way?' patient was seen again within 48 h; if the diastolic At the end of the placebo run-in period and at the pressure remained at least 115 mm Hg the patient end of the double-blind treatment period, patients was then withdrawn. rated (on a standard symptom questionnaire) how Compliance with treatment was assessed by tablet much they were distressed: (1 = not at all; 2 = a little counts at the end of the placebo run-in period and bit; 3 = moderately; 4 = severely) by the following 35 at the end of double-blind treatment. Smoking habsymptoms associated with antihypertensive drugs: its and alcohol consumption were recorded. abdominal pain, thirst, inability to concentrate, Supine and standing systolic (SBP) and diastolic nightmares, skin rash, impotence (men only), genBPs (DBP) were measured at all scheduled clinic eral weakness, rapid heart beat, cold fingers and visits, using respectively Korotkoff phases I and V.
toes, vomiting, swelling of feed or ankles, feeling Supine pressure was taken after the patient had depressed, confusion, coughing, itchy skin, blurred rested for 5 min, the last of three consecutive readvision, flushing, dry mouth, constipation, muscle ings being used for analysis. Standing pressure was cramps, inability to fall asleep, abnormal mood measured once after 2 min upright following the swings, vertigo or dizziness, shortness of breath, supine recordings. At the clinic visits for BP hair loss, dry eyes, slow heartbeat, nausea, heartmeasurement, patients were asked not to take their burn, diarrhoea, numbness or tingling in hands or medication at breakfast; instead, BP was measured feet, decreased interest in sex, wheezing, loss of on arrival at the clinic, tablets were then ingested, and BP recorded again 2 h later.
taste, and increased frequency of urination. (Figure 1 , Table 3 ). There were significant falls in this value from baseline for all treatment groups The statistical analysis was performed according to including placebo. During active nebivolol therapy, the 'intent-to-treat' principle, ie, on all patients ranthe falls in pressure at the two lowest daily doses of domized, regardless of their compliance with the nebivolol (0.5 and 1.0 mg) did not differ from plaprotocol. All statistical tests reported are two-tailed cebo, but at all three of the higher daily nebivolol and a P value р0.05 was considered significant, doses (2.5, 5.0 and 10.0 mg) diastolic pressure was unless specified otherwise. The end point evalusignificantly lower than with placebo. Comparison ation, ie, last available observation per patient, was of the outcomes at the different doses showed the considered as primary timepoint. The shift from 1.0 mg dose of nebivolol to be more effective than baseline (supine position) of DBP at trough drug 0.5 mg, and both 5.0 mg and 10.0 mg to be more level was defined as the primary measurement. For effective than 2.5 mg. The difference between 5.0 each continuous variable, a two-way analysis of and 10.0 mg was not significant. There was no variance (ANOVA) model with effects for treatment appreciable difference between the outcomes at 2 group and continent of origin (Europe or USA) was and 4 weeks of active therapy. As can be seen from used to detect an overall difference between the six Figure 1 and Table 3 , the changes in supine systolic treatment groups. When a statistical overall differpressure at trough drug level paralleled those in ence was noted, Dunnett's t-test, with placebo as refdiastolic pressure. BP values at trough and peak erence group, was subsequently performed to drug level (supine and standing), at the 4th week of account for multiple comparisons when investigatdouble-blind treatment, are shown in Table 3 . It is ing efficacy in the nebivolol groups versus placebo.
Statistical analysis
evident that similar dose-related falls in BP were Additional analyses were performed to characterize found at these measurements, and that only minor the within-group comparisons. To determine the variations occurred between peak and trough. The dose-response relationship, the Kodell-Chen closed trough-to-peak ratio for supine diastolic pressure trend test procedure 16 with one-tailed Jonckheerewith nebivolol 5 mg once daily was 0.894. There Terpstra trend test was performed at the 10% sigwas no appreciable postural component to the BP nificance level.
reduction. Trough-to-peak ratio was calculated for the supine Defining 'response' as an achieved supine dias-DBP as follows: 17 tolic pressure at trough drug level as р90 mm Hg and/or a fall in pressure from baseline of at least 10 trough peak = ⌬DBP, NEB, trough − ⌬DBP, PLAC, trough ⌬DBP, NEB, peak − ⌬DBP, PLAC, peak mm Hg, the response rates were: placebo 32%; and at the respective doses of nebivolol, 31%, 38%, where ⌬DBP = shift in DBP from baseline (ie, end 43%, 58% and 57%. BP reduction was unrelated point run-in) to the end of double-blind treatment.
to age. The influence of sex, age and race on the shift
In each treatment group, notably also including from baseline of trough diastolic pressure in supine those taking placebo, the decrease in supine diaposition was investigated by means of a two-way stolic pressure at trough drug level was greater in ANOVA with treatment and separately, each of the women, the mean difference at 5 mg nebivolol daily characteristics as main effects. In the case of a sigbeing 1.1 mm Hg. Overall the difference between nificant effect, Dunnett's t-test was used to investiwomen and men in this respect was nominally siggate the difference of the nebivolol treatment groups nificant (P = 0.039), although the baseline values in from placebo in each stratum separately. the two sexes were similar. Nebivolol was no less effective in black than in non-black subjects. At the 5 mg dose, comparative Results falls in BP on average, black vs non-black, baseline to end of study, were, at trough drug level 9.7/8.5 Five hundred and nine patients were entered, the numbers in each treatment group being similar vs 9.0/9.4 mm Hg, and at peak 12.7/8.4 vs 12.6/11.9 mm Hg; while the respective response rates were (placebo n = 84; nebivolol groups respectively 0.5, 1.0, 2.5, 5, 10 mg: n = 83, n = 87, n = 85, n = 86, and 62% vs 57%. Heart rate was slowed by nebivolol in a dosen = 84). Fifty-three per cent of the patients were men. The mean age of all patients at entry was 56 related fashion, with a maximum fall of some 10 beats per minute, standing, at peak drug level, simiyears (range 24-70). Seventy per cent were Caucasian, 22% were black, and 7% of Hispanic origin. A lar with 5 and 10 mg daily. ECG confirmed the above clinically assessed changes in heart rate, and low salt diet was taken by 42% and alcohol by 47%, while 23% were smokers. Twenty-two patients took additionally showed dose-related increases in QT (with a maximum of 17.2 msec at nebivolol 10 mg), a constant daily dose of aspirin, and 22 others a constant daily dose of other non-steroidal anti-inflamwith a decrease in QTc intervals (with a maximum of 6.3 msec at nebivolol 5 mg) , as is usual with other matory drugs during the trial.
Compliance with therapy, as assessed by tablet beta-blockers. 18 There were no consistent or clinically relevant count, was more than 98% in all treatment groups. Individual compliance of less than 80% was found changes in body weight, in biochemical or haematological values or on urine testing. in one patient in the placebo group, and in the nebivolol groups respectively 0, 3, 1, 2 and 1.
Fifteen patients withdrew because of supposed adverse effects of drug therapy during double-blind The primary trial criterion was the achieved supine diastolic pressure at trough drug level treatment. Two of these were taking placebo, while at the respective nebivolol doses there were 3, 2, 3, all, there were similar numbers of improvements and deteriorations reported. Table 4 shows the most 2 and 3 withdrawals. There was no clear pattern to these reported reactions, and none was evidently frequent adverse events reported spontaneously on placebo and on the various doses of nebivolol durdrug-related.
Over the month of double-blind treatment, the ing double-blind treatment. As can be seen, the type and incidence of such events was similar on placebo mean total symptom score did not worsen in any of the treatment groups, and there was no change in and active nebivolol, and was not in the latter case dose-related. the mean score for any individual symptom. Over- distinct, but not excessive, fall in heart rate. No ageDiscussion related antihypertensive effect was discerned. The The present trial has confirmed that nebivolol is an drug was well tolerated, even in doses of 10 mg effective antihypertensive agent given once daily, daily. The pattern of reported adverse events without appreciable differences in BP level between double-blind did not differ between placebo and peak and trough drug levels. This is an important nebivolol, and was moreover not dose-related. These point, because efficacy is thereby achieved whilst findings are gratifying, whilst being subject to the avoiding high plasma concentrations of drug with unavoidable caveat that such assessments are necesany consequent attendant potential problems.
sarily limited in sensitivity. At the recommended Lipicky 19 has stated that if 50-75% of the peak effect definitive dose of 5 mg once daily, nebivolol of a dose is preserved at trough, issues concerning achieved an antihypertensive effect comparable to the proper dosing interval do not arise; the closer to that of standard beta-blocking drugs, but with few of no loss of effect throughout the dosing interval the the side effects usually accompanying such therapy. better. Nebivolol 5 mg once daily, with a figure of
The combination of properties of nebivolol, notably 89%, clearly surpassed that standard. The duration its possession of beta-adrenergic blockade with of antihypertensive effect of different beta-blockers vasodilation and potentiation of nitric oxide effects varies widely. 20 It remains uncertain how long the on arterial and venous endothelium is especially effect of a dose of atenolol, a standard beta-blocker, attractive. Enhancement of vascular endothelial and will last, although a single daily dose is often consmooth muscle nitric oxide has been proposed as sidered to be satisfactory. 20 It has been demonstrated beneficial not only in lowering high BP, but also in that active hydroxymetabolites can sustain the antimoderating associated atherosclerosis.
26,27
The hypertensive effect of native nebivolol. 21 A single present trial accords well with the former suggesdaily dose of 5 mg appears to be appropriate, with tion. Substantiation of the second proposal must no evident antihypertensive advantage at 10 mg. await further study. The similar efficacy of nebivolol in black as in Beta-adrenergic blocking drugs are now wellnon-black patients is noteworthy and gratifying. It established as initial therapy in essential hypertenhas been emphasized that black Americans are often sion. 18, 22 Nebivolol, a long-acting, vasodilating betacomparatively poorly responsive to standard betablocker which is highly cardioselective, has conblocking drugs. 22 siderable potential in this context. The greater antihypertensive response in women than in men is unexplained. While it is tempting to Participating physicians ascribe this to some particular property of nebivolol, that it was also seen with placebo engenders cauFrance: D De Treglode (Quimperle), P Wahl (SaintMichel). tion. No such differential, either on active drug or placebo, was observed in earlier trials. [23] [24] [25] This Germany: R Buck (Budelsdorf), E Homsy (Ludwigshafen), G Kleinmanns (Dü sseldorf), H aspect merits attention in other trials employing nebivolol, although it may well be simply a chance Mauersberger (Villingen-Schwenningen), I Naudts (Dudenhofen), G Preissler (Puchheim), K Winn finding. No orthostatic component to the BP reduction was seen. Absence of postural hypoten-(Hannover). Italy: V Cagli (Rome), L Corea (Perugia), C Di Veroli sion is a feature of many beta-blockers, although it can appear with beta-blockers also having a vaso-(Rome), C Lai (Cagliari). The Netherlands: ER Coene (Zeist), CHL Klaassen dilator action, especially if there is an alpha-blocking component, such as with labetalol or carvedi-(Beverwijk), C Oldenbroek (Hoorn), AJ te Rijdt (Hengelo), MJ van der Horn (Ijmuiden), GJM van der lol. 18 The lack of postural hypotension with nebivolol is thus noteworthy. Nebivolol caused a Linden (Dordrecht).
